Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Shareholder Meeting (August 2022)
19 slides from Aarti Drugs's shareholder meeting presentation, Aug 4, 2022
Slide 1: Aarti Drugs Limited stock exchange cover letter
-- a=- Aarti Drugs Limited Corporate Office : Mahendra Industrial Estate Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com ' Manufacturer
Slide 2: Annual General Meeting August 4, 2022
AARTI DRUGS LIMITED Annual General Meeting August 4, 2022
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Company Overview
3 Company Overview
Slide 5: Key Milestones
Key Milestones 2022 Consolidated Revenue Rs. 2,500 Cr 2017 Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2020 Crossed Rs. 2,000 Cr 2003 Consolidated Turnover & Rs. 1996 Listed On National Stock 200 Cr Formulations Turnover Amalgamation of Rupal Chemical Exchange of India Limited In
Slide 6: Key Facts & Figures
Key Facts & Figures Largest producer of Nimesulide in the world. 12 4,077 Manufacturing MT/Monthly Facilities Capacity Largest producer of Metronidazole in Largest producer of India Ketoconazole in the world 80+ 1,10,330 Finished Products Sq.m Plant Area Leadership in API One of the leading Manufact
Slide 7: State-of-the-art Integrated manufacturing facilities
State-of-the-art Integrated manufacturing facilities Baddi Pinnacle Plant Formulation Plant WHO-GMP Sarigam-1 WHO-GMP Sarigam-2 WHO-GMP/ COFEPRIS/CEP E-22 W-61 Australian Government – Department of Health and EUGMP & WHO-GMP Ageing - Therapeutic Goods Administration EUGMP / WHO-GMP / Japanese Ac
Slide 8: Diversified geographic presence
Diversified geographic presence Presence in 100+ Countries across Top 10 Countries - Exports 6 Continents ensures Brazil Mexico diversification and risk minimization Pakistan Turkey Europe Indonesia UAE 12% 12% Egypt Bangladesh FY21 FY22 Asia Switzerland Germany North America Market 58% 54% FY21 FY2
Slide 9: ESG Initiatives
ESG Initiatives Environmental Social Governance • Converted multiple facilities into to Zero • Woman Empowerment: Free Government • The Board has an optimum combination of Liquid Discharge (ZLD) approved and certified vocational course training Executive and Non-Executive directors and • Dual Fired
Slide 10: Corporate Social Responsibility
Corporate Social Responsibility Donation of Inverter, Water filters, Air coolers Steel cupboards, Table chair sets, Washing Machines, Wooden Medicine Racks, Examination Stools to Coconut Tree Plantation various villages 9
Slide 11: Capex to drive the next leg of growth
Capex to drive the next leg of growth Capex of Rs. 600 crores underway [starting from FY22 for the next 4-5 years] Capex plans Phase wise capex will lead to distributed investments Majority of the capex to be funded through internal accruals and minimal debt Brownfield expansion and debottlenecking
Slide 12: Financial Highlights of FY22 and Q1FY23
11 Financial Highlights of FY22 and Q1FY23
Slide 13: FY22 Result Highlights
FY 22 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 20.5% 13.7% 13.0% 8.2% +16% 2,500 442 280 2,159 341 205 FY21 FY22 FY21 FY22 FY21 FY22 1. EBITDA includes other income & excludes exceptional items 2. Exceptional items includes profit on sale of assets of Rs.
Slide 14: Q1FY23 Result Highlights
Q1FY23 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 14.0% 12.8% 10.8% 8.4% 8.0% 5.6% 694 89 55 622 81 49 580 67 35 Q1 FY22 Q4 FY22 Q1 FY23 Q1FY22 Q4 FY22 Q1 FY23 Q1 FY22 Q4 FY22 Q1 FY23 1. EBITDA includes other income & excludes exceptional items 14
Slide 15: FY22 Segmental Break-up
FY22 Segmental Break-up FY21 FY22 11% 13% 4% 79% 4% 80% 5% 4% API Formulation API Formulation Speciality Chemicals Intermediates & Others Speciality Chemicals Intermediates & Others 15
Slide 16: Historical Performance At A Glance
16 Historical Performance At A Glance
Slide 17: Strong Financial Performance
Strong Financial Performance Consolidate d Revenue (Rs. Crores) EBITDA (Rs. Crores) PAT (Rs. Crores) 2,500 442 280 2,159 341 205 1,808 1,563 263 1,245 210 141 200 82 90 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 EBITDA Margin (%) PAT Margin (%) 20.5% 13.0% 16.0% 14.6%
Slide 18: Strong Financial Performance
Strong Financial Performance Consolidated EPS* (in Rs.) Net Worth (in Rs. Crores) Leverage (X) 30.1 1,036 1.2 913 22.1 0.9 653 15.4 544 0.6 455 0.5 8.6 9.6 0.4 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 * For EPS, adjusted includes previous year’s figures in proportio
Slide 19: Distribution to Shareholders
Distribution to Shareholders Distribution Policy Distributed ~Rs. 67.9 Crores as Dividend over last 7 years Distribution: ~21.5% Considering various financial parameters, the Company Distributed ~ Rs. 203.8 crores may elect to distribute about in form of dividend & buyback 15% to 30% of of shares ov